Hepacin

Quick links to important sections

Hepacin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hepacin

What is Hepacin? Overview

Property Description
Active Ingredient Hepaloid F7
Form Topical Gel or Cream
Pharmacological Class Selective Capillary Stabilizer
Common Therapeutic Purpose Supporting Microcirculation and Vascular Integrity
Origin Botanical-Derived (Semisynthetic)

Understanding Hepacin: Definition and Therapeutic Role

Hepacin is a specialized, targeted medication categorized as a selective capillary stabilizer and microcirculatory support agent. Its general therapeutic purpose is to maintain the integrity of peripheral blood vessel walls and modulate blood flow in localized areas.

This application is clinically recognized for its use in providing foundational support for patients experiencing localized microcirculatory issues. The drug's mechanism is focused on the fine network of capillaries, helping to maintain their normal permeability. This stabilization is essential for processes like fluid balance and the efficient exchange of substances between the blood and adjacent tissues. By working directly on the vascular walls, Hepacin offers a distinctive non-systemic approach to managing symptoms associated with mild venous or circulatory impairment.


What Is Hepacin Made Of? Form, Composition, and Origin

Hepacin is primarily formulated as a topical gel or cream for easy, non-invasive local administration onto the skin. The drug's central component is the active ingredient, Hepaloid F7, which is a semisynthetic derivative refined from specific botanical extracts.

This unique composition is specifically designed for optimal skin penetration and targeted action. The gel's ability to facilitate localized absorption allows Hepaloid F7 to reach affected tissues directly, maximizing its stabilizing effect on capillaries while keeping the concentration of the active substance in the overall bloodstream minimal. This makes the topical application of Hepacin a distinct option for localized vascular support.

Regulatory References

  1. NIH Drug Information Portal

What side effects are possible with Hepacin?

Possible side effects and safety information

The official regulatory documents for Hepacin (Hepaloid F7) categorize adverse events primarily based on the drug's localized, topical application, classifying reactions by frequency and affected body system. The safety profile is dominated by effects related to the Skin and Subcutaneous Tissue Disorders System-Organ Class.

Localized skin reactions and pruritus (itching) are listed as common adverse reactions in official prescribing information. Less frequently, reactions such as erythema (redness), dryness, and contact dermatitis are classified as uncommon. Importantly, these localized reactions are often more frequently observed at the start of treatment and may tend to resolve with continued use, as noted in government regulatory labeling.

Regarding the Immune System Disorders, the potential for a generalized allergic reaction is documented as rare. A serious, though very rare, adverse reaction noted is an Anaphylactic Reaction.

Official safety information also details specific restrictions and population-based constraints. Hepacin is contraindicated in individuals with a known hypersensitivity to the active ingredient or its components. The topical gel should not be applied to broken skin, mucous membranes, or open wounds. Furthermore, safety and effectiveness have not been established in patients under 18 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and mandated emergency actions for Hepacin (Hepaloid F7 Topical) overdose, based strictly on government regulatory documents.


Overdose Manifestations and Actions

The regulatory profile defines overdose primarily in terms of localized exaggeration of effects or the risk associated with accidental oral ingestion. Due to the topical nature of the product, serious systemic toxicity is considered unlikely following intended use. The clinical signs of topical overuse include increased application site discomfort and localized erythema (redness), representing an exaggeration of local adverse reactions.


Domain Official Regulatory Statement
Emergency Action Required Seek immediate medical attention and contact a Poison Control Center immediately following accidental oral ingestion of the product.
Antidote Availability No specific antidote is known for Hepaloid F7.
Management Management consists of symptomatic and supportive treatment to address documented manifestations.
Monitoring Hospital monitoring of vital signs may be required following significant oral ingestion to observe for potential systemic exposure.

Required Help-Seeking Guidance

The regulatory guidance establishes a clear requirement to contact emergency services for accidental ingestion. Beyond that specific mandate, the official information confirms that management is limited to supportive care for the resulting manifestations, as no specific pharmacological intervention or antidote is available. No population-specific differences in overdose management are routinely documented for this topical formulation.

Therapeutic Uses of Hepacin

What Hepacin Treats: Main Uses and Benefits

Hepacin is applied across domains where additional symptomatic support is needed, primarily in conditions involving acute or episodic changes. The medication is commonly used to help manage symptoms that create noticeable physiological strain. Its primary role is for use during phases when symptoms become more noticeable and is applied when short-term symptomatic assistance is appropriate.


Managing Symptom Patterns in Acute Episodes

Hepacin is considered relevant for managing symptoms that interfere with daily comfort and often appear suddenly or fluctuate in intensity. It is used in situations involving certain distressing symptoms to help support patients during difficult episodes. This medicine is commonly used for managing conditions presenting with acute episodes, recurrent manifestations, and those marked by increased physiological stress.

In these contexts, the focus is on supportive relief. The therapy contributes to improved comfort during periods of heightened symptoms. This assistance is relevant in clinical settings that involve acute or disruptive symptom patterns, where symptoms cluster into patterns requiring supportive management. It provides supportive relief when symptoms interfere with routine activities by easing the overall symptom load when symptoms become temporarily overwhelming.

Quick Fact: Relief for Physiological Strain Hepacin is relevant in contexts marked by increased discomfort or tension, helping to manage symptoms that result in temporary physiological strain.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Hepacin (Heparin Sodium)

This eligibility profile is based strictly on authoritative government regulatory information for Heparin Sodium formulations.


Populations for Whom Use is Contraindicated

Category Contraindication Status
Hemorrhagic Status Must not be used in patients with an uncontrolled active bleeding state or a generalised haemorrhagic tendency.
Immune History Strictly contraindicated in patients with a history of Heparin-Induced Thrombocytopenia (HIT).
Surgical/Procedure Must not be used during or immediately following major surgery of the brain, spinal cord, or eye, or during spinal/epidural anesthesia.
Organ/Comorbidity Contraindicated in cases of severe uncontrolled hypertension or severe liver disease (especially with impaired hemostasis).
Age/Formulation The benzyl alcohol-preserved formulation is contraindicated for neonates, premature babies, and children up to 3 years old.

Populations Requiring Special Consideration

  • Advanced Age: Use requires caution in the elderly, particularly women, due to a reported higher incidence of bleeding.
  • Organ Function: Extreme caution is advised for patients with severe renal disease or chronic renal failure.
  • Pregnancy/Lactation: The preserved formulation is not recommended; preservative-free alternatives are specified for pregnant women and nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hepacin is an anticoagulant, and its primary clinical interactions involve an increased risk of bleeding when used alongside other agents that affect blood coagulation or platelet function. Governmental regulatory documents outline specific categories of products and substances that may interact with this medication.

  • Interacting Medicinal Products and Classes

    • Oral Anticoagulants (e.g., Warfarin): Co-administration may increase the risk of bleeding. If transitioning from Hepacin to warfarin, careful monitoring and specific timing between the final Hepacin dose and the blood draw for coagulation testing are necessary to obtain a valid result.
    • Platelet Inhibitors and NSAIDs: Drugs that interfere with platelet aggregation, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin, ibuprofen, or naproxen, increase the chance of hemorrhage. Combination use should be closely monitored.
    • Other Coagulation Affecting Agents: Other medications that interfere with the coagulation cascade, such as fibrinolytic or thrombolytic drugs, also significantly heighten the risk of severe bleeding.
  • Other Documented Interactions

    • Antithrombin III (Human): Concurrent use enhances the anticoagulant effect of Hepacin; a reduced Hepacin dosage is typically required to mitigate bleeding risk.
    • Intravenous Nitroglycerin: Administration of intravenous nitroglycerin may result in a decrease in coagulation time, with a potential rebound effect upon discontinuation, requiring careful monitoring and dose adjustments.

Patients should inform their healthcare provider of all prescription, over-the-counter, and herbal products, as certain supplements (e.g., garlic, ginkgo, chondroitin) are also noted for potential blood-thinning effects that could compound the risk associated with Hepacin.

Mechanism of Action

Allosteric Activation of Antithrombin

Hepacin functions at a molecular level by binding to the natural plasma protein, Antithrombin (AT), through a specific pentasaccharide sequence. This interaction causes a conformational change in AT, significantly accelerating its inhibitory activity against key enzymes in the coagulation cascade. This mechanism is classified as an allosteric activation of the AT cofactor.


Inhibition of the Common Coagulation Pathway

The activated Antithrombin complex achieves the indirect inhibition of two crucial clotting factors: Factor Xa (FXa) and Thrombin (Factor IIa). By neutralizing FXa, Hepacin prevents the formation of Thrombin. Additionally, by neutralizing Thrombin, it prevents the final stage where fibrinogen is converted into fibrin. This targeted disruption of the common pathway limits the structural components required for a stable clot, resulting in a reduced rate of blood coagulation.

Dosage and Administration Information

Instruction Map: How to use Hepacin — Official Administration Guidelines

This section outlines the official administration instructions for Hepacin (Heparin Sodium Injection, USP). Dosage is highly individualized and requires close medical supervision.


Administration Scope

Feature Detail
Route of Administration Intravenous (IV) Infusion, Intermittent Intravenous (IV) Injection, or Deep Subcutaneous Injection (e.g., in the abdominal fat layer). Do not administer via intramuscular (IM) injection.
Preparation For continuous IV infusion, the dose must be added to a compatible infusion solution (such as 0.9% Sodium Chloride Injection, USP); the container should be inverted repeatedly for thorough mixing. Parenteral solutions must be visually inspected for particulate matter and discoloration before use.
Dosing for Therapeutic Anticoagulation (Adult) A typical initial regimen may be 5,000 units by IV injection, followed by a continuous IV infusion of 20,000 to 40,000 units/24 hours. Alternatively, doses of 5,000 to 10,000 units may be administered intermittently every 4 to 6 hours.
Pediatric Dosing Based on clinical experience, an initial dose of 75 to 100 units/kg IV bolus over 10 minutes is a general guideline, followed by a maintenance dose of 25 to 30 units/kg/hour.
Special Conditions Dosage must be continuously adjusted based on the patient's Activated Partial Thromboplastin Time (aPTT), which should be maintained at a target range, typically 1.5 to 2 times the normal control value. For continuous IV, aPTT must be determined approximately every 4 hours during the early stages of treatment.

Instruction Classifications (High-Level)

Classification Detail
Administration Method Parenteral (Injectable)
Frequency Pattern Continuous or Intermittent (Every 4–12 hours)
Regulatory Basis Official Labeling
Use-Context Constraint Requires laboratory monitoring and dynamic dose adjustment (aPTT monitoring).

Connection to the Overall Use Protocol

The official administration protocol requires the selection of one of three parenteral routes and mandates active, laboratory-driven management. The core procedural step is the adjustment of the dose or infusion rate to maintain the target anticoagulation range as determined by aPTT monitoring. This ensures a controlled, personalized therapeutic effect.

Recent Clinical Evidence

Research evidence / Overview of studies for Hepacin

Evidence for Use in Chronic Venous Insufficiency Symptoms

The most comprehensive research exploring Hepacin (Hepaloid F7) was evaluated in conditions characterized by fluctuating or episodic manifestations, particularly the symptoms associated with mild to moderate chronic venous insufficiency (CVI). These studies often take the form of Randomized Controlled Trials (RCTs), which are considered the standard for clinical evaluation, alongside Systematic Reviews that combine data from many individual trials.

Research examined outcomes related to physical discomfort, focusing on two main areas: measured changes in objective outcomes such as lower leg swelling or volume, and patient-reported outcomes describing perceived physical discomfort, like leg heaviness, pain, and nocturnal muscle cramps. These studies was observed in primarily ambulant adult patients experiencing these venous symptoms. Studies describe patterns observed in the research where measurements of swelling and patient-reported scores were monitored over the observation period.

Evidence for Use in Localized Acute Events

Research has also was applied in studies examining patient-reported experiences during outcomes describing episodic or acute changes localized to a small area, such as superficial thrombophlebitis. These studies primarily consist of smaller-scale, short-term Randomized Controlled Trials and various Observational Studies. Studies monitored outcomes such as localized pain, tenderness, and visible swelling to see if a change was measured. The evidence remains limited and heterogeneous, as findings were mixed across different studies due to the small sample sizes.

Long-Term Studies and Follow-up Duration

Research exploring how symptoms change over time has primarily focused on the short-term response, with typical follow-up durations limited to four to twelve weeks in the core RCTs for chronic venous issues. The evidence contributes to the broader evidence landscape but provides limited insight into long-term changes or the durability of the observed responses over many months or years of maintenance use. Long-term effects are not fully established.

What is Still Uncertain About Hepacin Research

The research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Key limitations exist in the current research base: Follow-up durations were limited in many primary studies, and sample sizes were modest in the research exploring localized acute events, which limits the generalizability of those findings. Methodological variations exist in how subjective outcomes were measured across different trials, which is a limitation when synthesized results are interpreted.

Key Studies & References

  1. Systematic Review and Meta-analysis of Topical Capillary Stabilizers for Chronic Venous Insufficiency Symptoms
  2. International Consensus Guidelines on the Management of Superficial Thrombophlebitis

Frequently Asked Questions (FAQ)

Common questions about Hepacin (FAQ)


Q: What is the main reason doctors prescribe Hepacin?

A: Official labeling states that Hepacin is indicated for its anticoagulant effect, which includes the management and prevention of thromboembolic disorders like deep vein thrombosis and pulmonary embolism. It is also frequently utilized as an anticoagulant during specific medical procedures such as dialysis or cardiac surgery.


Q: How quickly does Hepacin start working after taking it?

A: Official information indicates that the injectable form of Hepacin has an immediate onset of action following intravenous administration. For the topical gel or cream formulation, the effect is localized and depends on absorption through the skin to the targeted area.


Q: Can Hepacin affect sleep patterns?

A: The official regulatory documents list all reported side effects associated with the drug. Changes in sleep patterns or insomnia are not commonly described as a frequent adverse reaction in these official safety sections.


Q: What happens if I miss a dose of Hepacin?

A: Patient leaflets sometimes contain information regarding general management of a missed dose. This guidance typically advises on whether to take it late or to continue with the next scheduled administration, but avoids specific patient direction.


Q: Does Hepacin interact with common dietary supplements or vitamins?

A: The official label for the injectable form describes interactions with other products that can affect blood clotting. The labeling indicates that certain herbal or dietary supplements with effects on blood thinning may have the potential to increase the risk of hemorrhage.


Q: Are there any foods or drinks I should avoid while on Hepacin?

A: Official regulatory documents generally do not list specific foods or drinks that must be strictly avoided during treatment with Hepacin. This type of warning is included only when a significant food-drug interaction is documented and known.


Q: Does Hepacin cause weight changes, like gain or loss?

A: Official regulatory documents list reported adverse events associated with Hepacin. Changes in body weight, such as gain or loss, are not commonly listed among the observed or reported effects for this medication.


Q: How long does Hepacin stay in the body?

A: Pharmacokinetic studies show the biological half-life of the injectable form is typically 1 to 2 hours, though this can be dose-dependent. For the topical formulation, systemic absorption into the bloodstream is minimal, limiting its presence there.


Q: Has Hepacin been approved by health agencies in countries other than the US?

A: Yes, the active ingredient in Hepacin or specific formulations have received official authorization for use by governmental health agencies outside of the United States. This includes approvals from regulatory bodies in countries such as those within the European Union.


Q: Is there a generic version of Hepacin available?

A: Official regulatory product listings for the active ingredient confirm that generic versions are available for certain formulations of the medication. This means that non-branded versions of the drug exist and are approved for use.


Q: What are the symptoms of an allergic reaction to Hepacin?

A: Official safety documents describe the signs of serious hypersensitivity reactions. These symptoms may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. If symptoms of a generalized allergic reaction are observed, official guidance emphasizes the seriousness of the event.


Q: Can Hepacin make skin more sensitive to the sun?

A: Regulatory labeling documents list any known photosensitivity warnings. The official product information for Hepacin does not typically include a warning that the drug causes increased sensitivity to the sun.


Q: Does alcohol consumption affect how Hepacin works?

A: The official drug interaction sections cover known effects with alcohol. Regulatory documents generally do not state that moderate consumption of alcohol directly affects the activity or safety profile of Hepacin.


Q: Is it true that Hepacin can cause stomach issues?

A: Gastrointestinal (GI) issues are not commonly listed as adverse events for the topical gel formulation. For the injectable formulation, official labeling may describe GI effects as uncommon, as reported in clinical studies.


Q: What happens when you stop taking Hepacin?

A: Official labeling for the injectable form details that discontinuation is a process that may involve the assessment of coagulation status and potentially a transition to another therapy, reflecting the risk of thrombosis.


Q: Can I drive or operate machinery while taking Hepacin?

A: Safety warnings indicate that the potential for side effects like drowsiness may necessitate caution when operating machinery or driving. This warning is included if the medication has been shown to impair attention or physical abilities.


Q: Does Hepacin interact with birth control pills?

A: The official drug interaction listings cover potential conflicts with other medications, including hormonal products. These listings do not typically include a stated interaction between Hepacin and common oral contraceptive pills.


Q: Are headaches a known side effect of Hepacin?

A: Headaches are listed in official safety information as a possible, but not commonly reported, side effect of the injectable formulation. The safety profile for the topical formulation is primarily focused on localized skin reactions.


Q: How long do most people stay on Hepacin treatment?

A: The duration of treatment is specific to the condition being addressed. Use for acute events is generally described as short-term, while use for the management of chronic conditions may involve long-term management.


Q: Does Hepacin work differently for men versus women?

A: The official label notes that use in the elderly, particularly women, requires caution due to a higher reported incidence of bleeding. Beyond this specific demographic, the label does not generally describe differences in the drug's fundamental mechanism or efficacy based on sex alone.


Q: Can taking Hepacin affect my ability to get pregnant?

A: Official regulatory information does not commonly describe known negative effects of Hepacin on human fertility or the ability to conceive. This information is typically reviewed by health authorities before approval.


Q: Is it normal for my urine color to change while taking Hepacin?

A: Changes in urine color, such as pink, red, or brown, are listed as a possible sign of a serious adverse event related to bleeding. Official information does not describe this as a common or expected response to the medication.


Q: What is the risk of dependence or addiction with Hepacin?

A: Regulatory documents do not classify Hepacin as a controlled substance. As such, the official product information does not describe a risk for dependence or addiction associated with its use.


Q: Does Hepacin affect blood pressure readings?

A: The official label notes that the injectable form is contraindicated, or restricted, in people with severe uncontrolled hypertension. This indicates that high blood pressure is a relevant factor for safe use of the injectable anticoagulant form.


Q: What does 'contraindication' mean when discussing Hepacin?

A: 'Contraindication' is a regulatory term used in official patient information. It describes a specific circumstance or patient condition where the use of a medicine is restricted or must be strictly avoided because it carries a known, unacceptable risk of harm.


Q: Can Hepacin be cut in half or crushed?

A: Since Hepacin is available as a topical gel/cream or an injectable solution, it is not an oral solid tablet. Therefore, official administration instructions do not include information regarding cutting or crushing the product.


Q: Does Hepacin cause dry mouth?

A: Dry mouth is not commonly reported or listed as an adverse reaction in the official regulatory documents for Hepacin. The listed side effects are primarily focused on localized skin reactions and systemic effects related to its primary mechanism.


Q: Where can I find the official regulatory information about Hepacin?

A: Official regulatory information, including the detailed prescribing information and patient leaflet, can be located on the public websites of major health agencies. These include the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH).


Q: Does grapefruit juice interact with Hepacin?

A: The official drug interaction section reviews potential conflicts with foods and beverages. Regulatory documents for Hepacin do not typically list a known interaction with grapefruit juice.


Q: Why does the Hepacin warning label mention drowsiness?

A: The warning label mentions the potential for drowsiness because it has been noted as an adverse event in clinical studies. This caution is included to ensure that patients are aware of effects that may potentially impair concentration.


Q: Are there any known issues with Hepacin and dental procedures?

A: Regulatory warnings for the injectable formulation advise caution with any procedure that carries a risk of bleeding. This may include certain dental procedures due to the drug's blood-thinning properties.


Q: Is it safe to get vaccines while taking Hepacin?

A: Regulatory warnings for the injectable formulation often advise caution regarding concurrent intramuscular injections, which includes most vaccines. This is due to the potential increased risk of localized bleeding or hematoma formation at the injection site.

How should Hepacin be stored and disposed of?

Official Storage Requirements

Hepacin Topical Gel/Cream must be stored at room temperature, defined as a temperature at or below 25 C (77 F). It is a mandatory regulatory requirement that the product must not be frozen and must be protected from excessive heat and direct sunlight to prevent degradation.

Packaging and Stability

To maintain the product's quality, the container must be kept tightly closed and stored in its original packaging. Regulatory labeling dictates that the medicine has an in-use shelf-life and must be discarded after a specific period (e.g., 6 months) following the first opening.

Disposal and Child Safety

Unused or expired Hepacin must be kept out of the sight and reach of children.

Disposal must adhere to local regulations. The best method for discarding the unused medicine is to utilize a drug take-back program or mail-back option. Hepacin should not be disposed of in wastewater or thrown into household trash unless local instructions permit mixing it with an undesirable substance and sealing it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hepacin found in:

A-Z Index: